- Home
- GCI vs ARVN Comparison
GCI vs ARVN Comparison
Compare GCI & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GCI
- ARVN
- Stock Information
- Founded
- GCI 1997
- ARVN 2015
- Country
- GCI United States
- ARVN United States
- Employees
- GCI N/A
- ARVN N/A
- Industry
- GCI Newspapers/Magazines
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- GCI Consumer Discretionary
- ARVN Health Care
- Exchange
- GCI Nasdaq
- ARVN Nasdaq
- Market Cap
- GCI 509.6M
- ARVN 456.2M
- IPO Year
- GCI N/A
- ARVN 2018
- Fundamental
- Price
- GCI $3.31
- ARVN $7.44
- Analyst Decision
- GCI Buy
- ARVN Buy
- Analyst Count
- GCI 3
- ARVN 21
- Target Price
- GCI $5.70
- ARVN $20.53
- AVG Volume (30 Days)
- GCI 1.6M
- ARVN 2.3M
- Earning Date
- GCI 07-31-2025
- ARVN 07-29-2025
- Dividend Yield
- GCI N/A
- ARVN N/A
- EPS Growth
- GCI N/A
- ARVN N/A
- EPS
- GCI 0.36
- ARVN N/A
- Revenue
- GCI $2,445,127,000.00
- ARVN $426,900,000.00
- Revenue This Year
- GCI N/A
- ARVN $4.26
- Revenue Next Year
- GCI N/A
- ARVN N/A
- P/E Ratio
- GCI $9.22
- ARVN N/A
- Revenue Growth
- GCI N/A
- ARVN 498.74
- 52 Week Low
- GCI $2.55
- ARVN $5.90
- 52 Week High
- GCI $5.93
- ARVN $34.11
- Technical
- Relative Strength Index (RSI)
- GCI 40.71
- ARVN 51.46
- Support Level
- GCI $3.33
- ARVN $7.12
- Resistance Level
- GCI $3.54
- ARVN $7.85
- Average True Range (ATR)
- GCI 0.16
- ARVN 0.43
- MACD
- GCI -0.03
- ARVN 0.05
- Stochastic Oscillator
- GCI 2.20
- ARVN 48.05
About GCI Gannett Co. Inc.
Gannett Co Inc is a digital newspaper company providing local media and marketing solutions in the U.S. The group operates in three segments, Domestic Gannett Media, Newsquest, and Digital Marketing Solutions. The majority of revenue is from the Domestic Gannett Media segment. The company's brands include USA TODAY and more than 250 daily newspapers as well as digital marketing services companies, including ReachLocal, WordStream, and others. The company produces more than 350 annual events, such as themed expos. The company also operates in the U.K. through the U.K. media company Newsquest, providing more than 150 local media brands.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.